Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

被引：0
|
作者：
Davide Melisi
Rocio Garcia-Carbonero
Teresa Macarulla
Denis Pezet
Gael Deplanque
Martin Fuchs
Jorg Trojan
Helmut Oettle
Mark Kozloff
Ann Cleverly
Claire Smith
Shawn T. Estrem
Ivelina Gueorguieva
Michael M. F. Lahn
Al Blunt
Karim A. Benhadji
Josep Tabernero
机构：
[1] University of Verona,Oncology Department
[2] Piazzale Ludovico Antonio Scuro,undefined
[3] Hospital Universitario 12 de Octubre,undefined
[4] Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12),undefined
[5] UCM,undefined
[6] CNIO,undefined
[7] CIBERONC,undefined
[8] Vall d’Hebron University Hospital Institute of Oncology (VHIO),undefined
[9] CIBERONC,undefined
[10] C/ Natzaret,undefined
[11] 115-117,undefined
[12] Centre Hospitalier Universitaire,undefined
[13] Hôpital Riviera-Chablais,undefined
[14] Klinikum Bogenhausen,undefined
[15] Städtisches Klinikum München GmbH,undefined
[16] Goethe University Medical Center,undefined
[17] Onkologische und Hämatologische Schwerpunktpraxis,undefined
[18] Ingalls Memorial Hospital,undefined
[19] Eli Lilly and Company,undefined
[20] Erl Wood Manor,undefined
[21] Windlesham,undefined
[22] formerly of Eli Lilly and Company,undefined
[23] Eli Lilly and Company,undefined
[24] Lilly Corporate Center,undefined
[25] 6820 Wisconsin Ave.,undefined
[26] #8008,undefined
[27] Advaxis,undefined
[28] Inc.,undefined
[29] Eli Lilly and Company,undefined
[30] Vall d’Hebron University Hospital and Institute of Oncology (VHIO),undefined
[31] CIBERONC,undefined
[32] Universitat Autònoma de Barcelona,undefined
[33] P. Vall d’Hebron 119-129,undefined
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1208 / 1214
页数：6
相关论文
共 50 条
  • [21] GEMCITABINE PLUS RADIOTHERAPY IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED PANCREATIC CANCER
    Otsuka, T.
    Kamachi, S.
    Akiyama, T.
    Fujimoto, M.
    Kawazoe, S.
    Ureshino, N.
    Watanabe, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 161 - 161
  • [22] Observational study of comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of metastatic pancreatic adenocarcinoma in the University Hospital Centre Zagreb
    Prejac, J.
    Gorsic, I.
    Vidovic, M.
    Golem, H.
    Kekez, D.
    Librenjak, N.
    Plestina, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 46 - 46
  • [23] Cisplatin, epirubicin, capecitabine, and gemcitabine (PEXG) as first-line treatment in metastatic or unresectable pancreatic cancer: Active and well tolerated?
    Rivalland, Gareth
    Lawrence, Benjamin James
    Mesnage, Soizick Jeanne Lynette
    Reeve, Jane
    Findlay, Michael P. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
    Lim, Jae Yun
    Cho, Jang Ho
    Lee, Se Joon
    Lee, Dong Ki
    Yoon, Dong Sup
    Cho, Jae Yong
    CANCER RESEARCH AND TREATMENT, 2015, 47 (02): : 266 - 273
  • [25] A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
    Oettle, H
    Richards, D
    Ramanathan, RK
    van Laethem, JL
    Peeters, M
    Fuchs, M
    Zimmermann, A
    John, W
    Von Hoff, D
    Arning, M
    Kindler, HL
    ANNALS OF ONCOLOGY, 2005, 16 (10) : 1639 - 1645
  • [26] Gemcitabine plus vinorelbine(GV) vs. gemcitabine plus paclitaxel(GT) vs. gemcitabine(G) vs. paclitaxel(T) in elderly NSCLC patients
    Frasci, G
    Lorusso, V
    Cornella, P
    Panza, N
    Nicolella, G
    Bianco, A
    De Cataldis, G
    Belli, M
    Iannelli, A
    Massidda, B
    Mancarella, S
    Masullo, P
    Comella, G
    De Luna, M
    ANNALS OF ONCOLOGY, 2000, 11 : 6 - 6
  • [27] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Petrillo, Angelica
    Pappalardo, Annalisa
    Pompella, Luca
    Tirino, Giuseppe
    Calabrese, Filomena
    Laterza, Maria Maddalena
    Caterino, Marianna
    Ventriglia, Anna
    Orditura, Michele
    Conzo, Giovanni
    Molino, Carlo
    Ciardiello, Fortunato
    Biglietto, Maria
    De Vita, Ferdinando
    MEDICAL ONCOLOGY, 2019, 36 (10)
  • [28] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Angelica Petrillo
    Annalisa Pappalardo
    Luca Pompella
    Giuseppe Tirino
    Filomena Calabrese
    Maria Maddalena Laterza
    Marianna Caterino
    Anna Ventriglia
    Michele Orditura
    Giovanni Conzo
    Carlo Molino
    Fortunato Ciardiello
    Maria Biglietto
    Ferdinando De Vita
    Medical Oncology, 2019, 36
  • [29] A phase II randomized trial of gemcitabine plus cisplatin(GP) vs gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple-negative breast cancer
    Gong, Chengcheng
    Zhao, Yannan
    Wang, Leiping
    Cao, Jun
    Tao, Zhonghua
    Li, Ting
    Zhao, Mingchuan
    Miao, Haitao
    Jin, Juan
    Hu, Xichun
    Wang, Biyun
    CANCER RESEARCH, 2024, 84 (09)
  • [30] Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients
    Pecora, I.
    Vivaldi, C.
    Rovesti, G.
    Catanese, S.
    Salani, F.
    Gardini, A. Casadei
    Massa, V.
    Bernardini, L.
    Riggi, M.
    Andrikou, K.
    Rapposelli, I.
    Formica, V.
    Cesario, S.
    Caccese, M.
    Lencioni, M.
    Vasile, E.
    Falcone, A.
    Fornaro, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S151 - S151
12345